You are here:

buprenorphine transdermal patch (Butec)

Advice

following a full submission

buprenorphine transdermal patches (Butec®) are accepted for restricted use within NHS Scotland.

Indication under review: In adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.

SMC restriction: for use in elderly patients (over 65 years).

Non-inferiority was demonstrated between buprenorphine weekly patches and twice daily oral tramadol in patients with moderate to severe osteoarthritic pain. Non-inferiority was also demonstrated between buprenorphine weekly patches plus oral paracetamol and co-codamol in patients with severe osteoarthritic pain.

Drug Details

Drug Name: buprenorphine transdermal patch (Butec)
SMC Drug ID: 1213/17
Manufacturer: Qdem Pharmaceuticals
Indication: In adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.
BNF Category:
Sub Category: 4.7 Analgesics
Submission Type: Full submission
Status: Restricted
Date Advice Published: 16 January 2017

Back